Inherited and Rare Kidney Diseases
River 3 Renal Corp. focuses on clinical research in Alport syndrome and primary steroid-resistant focal segmental glomerulosclerosis, with attention to renal disorders that cause progressive loss of kidney function and persistent proteinuria.
- Alport syndrome
- Primary steroid-resistant focal segmental glomerulosclerosis
- Proteinuria
The sponsor’s research activity in these conditions reflects a concentrated interest in nephrology and disease areas marked by hereditary and structural kidney pathology.
Diabetic Kidney Disease and Renal Injury
The clinical portfolio also includes diabetic kidney disease, extending the sponsor’s therapeutic interest to chronic kidney impairment associated with metabolic disease and renal damage.
- Diabetic kidney disease
- Albuminuria
- Chronic kidney impairment
This area places emphasis on kidney-related complications that are clinically relevant in both inherited and acquired renal disorders.
Renal Biomarkers and Disease Activity
Trial activity points to a strong focus on renal biomarker outcomes, particularly the reduction of proteinuria and albuminuria as indicators of kidney disease activity and treatment response.
- Proteinuria reduction
- Albuminuria reduction
- Kidney disease activity
These measures align the sponsor’s work with clinical endpoints commonly used in nephrology research.
Oral Therapeutics for Kidney Disorders
The sponsor is evaluating an orally administered renal therapy in patients with progressive kidney disease, indicating interest in oral treatment options for chronic kidney disorders.
- Oral administration
- Chronic kidney disorders
- Renal therapeutics
Current research activity spans multiple active trial sites across several countries, supporting work in multinational nephrology research.
